CTech 24/7

Generic

12 stories about Generic

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices
15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer GanonA 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose
21.04.19|Lilach BaumerCommonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars
08.01.19|Lilach Baumer and Hezi SternlichtSpeaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019
Teva Reaches Confidential Patent Settlement with Neos
27.12.18|CTechThe agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18|Lilach BaumerNovartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court
05.12.18|Lilach BaumerTeva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug
29.11.18|Lilach BaumerCalled Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma
Teva's American Dream Boat is Sinking
08.08.18|Uri Tal-TeneOver the past six quarters Teva's North American sales have been in free fall. The company's operating profit is in even worse shape. Mylan's decision to slash the price tag on its generic Copaxone offering further threatens Teva's revenues, meaning the company must hurry to provide the three potential trump cards it has up its sleeve
Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents
23.07.18|CTechIn September 2017, Allergan transferred six of its patents for blockbuster dry eye drug Restasis to the St. Regis Mohawk Tribe, hoping to protect the patents under the principle of sovereign immunity
Teva Increases Junk Senior Note Offering to $4.5 Billion
08.03.18|Lilach BaumerLast week the debt-laden drugmaker announced a $3.5 billion-equivalent offering to repay its short-term $1.5 billion outstanding debt due July
Berkshire Hathaway Takes Position in Generic Drugmaker Teva
15.02.18|Lilach BaumerThe holding company disclosed a $358 million stake in the struggling company
Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO
18.07.17|Golan HazaniMr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said

Twitter

Facebook

Rss

About CTech Terms of Use Privacy Policy

CTech 24/7

Generic

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

Teva Reaches Confidential Patent Settlement with Neos

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court

Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug

Teva's American Dream Boat is Sinking

Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents

Teva Increases Junk Senior Note Offering to $4.5 Billion

Berkshire Hathaway Takes Position in Generic Drugmaker Teva

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO